Recent News
- Biogen to seek approval for high-dose version of Spinraza for SMA
- Ubrelvy can prevent migraines when used early
- Leqembi® (lecanemab) authorised for early Alzheimer’s disease in Great Britain
- CREXONT for Parkinson’s disease – Amneal’s capsules gain FDA approval
- Valiltramiprosate -oral Aβ-targeting therapy for Alzheimer’s disease
- First-in-class therapy Cebranopadol for treatment of pain
- Alzheimer’s drug lecanemab rejected by EMA
- Pridopidine for ALS – promising results
- Managing drug resistant epilepsy (DRE)
- Data challenges migraine treatment pauses
Categories
- ACNR News (8)
- Acquired Brain Injury (12)
- Alzheimer's Disease (17)
- Amyotrophic Lateral Sclerosis (ALS) (6)
- Artificial Intelligence (4)
- Association of British Neurologists Trainees (4)
- Australia/New Zealand (1)
- Awards & Appointments (6)
- Book Reviews (2)
- Brain Mapping (1)
- Brain tumours (2)
- Case Reports (15)
- Charcot-Marie-Tooth Disease (1)
- Charity (5)
- Cognition (1)
- Comment (2)
- Course & Conference Previews (11)
- Courses & Conferences (1)
- COVID-19 Articles (3)
- Dementia (4)
- Epilepsy (13)
- Essay (1)
- Headache (15)
- Hereditary Spastic Paraplegia (1)
- Huntington's disease (2)
- Industry News (177)
- Journal Reviews (1)
- Major Depressive Disorder (3)
- Management Topics in Epilepsy (1)
- Multiple Sclerosis (23)
- Myasthenia Gravis (6)
- Neurodevelopmental disorders (2)
- Neuroimmunology (2)
- Neurological Literature (2)
- Neurology News (37)
- Neuropsychiatry (2)
- Neurosurgery (1)
- NHS News (2)
- Online First (14)
- Pain (4)
- Parkinson’s Disease (17)
- Rehabilitation (10)
- Rehabilitation Articles (4)
- Research (2)
- Sleep (1)
- Sleep Series (4)
- Special Feature (6)
- Sponsored Feature (7)
- Stroke (8)
- Stroke Series (3)
- Syncope (1)
- Uncategorised (43)
- Uncategorized (1)
